Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma. - Dummer R; Sandhu S; Miller WH Jr; Butler MO; Taylor MH; Heinzerling L; Blank CU; Couselo EM; Burris HA 3rd; Postow MA; Chmielowski B; Middleton MR; et al. (Future oncology (London, England), 2026)